The FKBP1A Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the Raji B lymphocyte cell line, featuring a targeted disruption of the FKBP1A gene. This knockout model provides a loss-of-function system to investigate FKBP1A-dependent signaling pathways in a human B-cell lymphoma background. The polyclonal format ensures a heterogeneous pool of gene-edited cells, enabling robust study of FKBP1A-mediated processes without clonal selection artifacts, making it suitable for diverse functional assays.
The Raji cell line, established from an Epstein-Barr virus (EBV)-positive Burkitt lymphoma, is a well-characterized model for B-cell biology, antigen presentation, and immune response studies. As B lymphocytes, Raji cells express surface markers and signal transduction machinery relevant to adaptive immunity, and their EBV association provides a context for oncogenic transformation and lymphomagenesis. This host background is particularly valuable for dissecting pathways that regulate proliferation, survival, and immune modulation in lymphoma.
FKBP1A encodes FKBP12, a peptidyl-prolyl isomerase that functions as a key immunophilin, binding immunosuppressive agents FK506 and rapamycin to modulate calcineurin and mTOR signaling, respectively. Upstream regulators include T-cell receptor/CD28 co-stimulation, calcium influx, and TGF-beta, while downstream targets encompass mTORC1, calcineurin, NFAT transcription factors, SMAD2/3, S6K1, and 4E-BP1. FKBP12 interacts with mTOR, calcineurin, TGFBR1, HSP90, and other FKBP12-rapamycin binding domain-containing proteins, thereby integrating immune inhibitory signals and protein folding networks. Through its isomerase activity, FKBP12 also facilitates protein folding and trafficking, and participates in TGF-beta receptor signaling regulation.
In Raji B lymphocytes, FKBP1A knockout disrupts the FKBP12-dependent modulation of mTOR and calcineurin pathways, which are critical for cell growth, proliferation, and immune responses. This disruption abrogates rapamycin- and FK506-mediated immunosuppressive effects, offering a valuable model to dissect drug mechanisms in lymphoma. Additionally, abrogation of FKBP1A function impairs TGF-beta-mediated growth inhibition and SMAD-dependent transcriptional responses, highlighting its role in B-cell lymphoma biology and potential therapeutic resistance mechanisms.
Typical research applications include studying FKBP1A-dependent mTOR and calcineurin signaling in B lymphocytes, screening immunosuppressive drug mechanisms in a lymphoma context, and investigating TGF-beta-mediated growth regulation. Key assays enabled by this model include Western blotting for phospho-S6K1 and phospho-4E-BP1 to assess mTORC1 activity, flow cytometry for B-cell surface marker expression changes, drug sensitivity assays with rapamycin or FK506, RT-qPCR for NFAT target genes, and co-immunoprecipitation to examine FKBP1A-mTOR interactions. For additional technical information or custom requests, please contact Ascent Research.
